Showing results (451-460 of 531) with videos related to

Sort By:
Pageof 54
The Oncologist|December 21, 2018
Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective AnalysisSteven M Bair, Lauren E Strelec, Tatyana A Feldman, et al.
Nature Communications|August 12, 2021
ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancerRokana Taftaf, Xia Liu, Salendra Singh, et al.
Blood Advances|November 21, 2024
Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomasElise A Chong, Elicia Penuel, Ellen B Napier, et al.
American Journal of Hematology|April 15, 2025
Autologous Transplant or CAR-T as Consolidation Options in MYC Rearranged Large B-Cell Lymphoma Patients in Remission After Salvage TreatmentsFateeha Furqan, Kwang W Ahn, Manmeet Kaur, et al.
Blood|October 24, 2024
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapiesLaurie H Sehn, Nancy L Bartlett, Matthew J Matasar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2024
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II StudyLihua E Budde, Sarit Assouline, Laurie H Sehn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2009
A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemiaAlexander E Perl, Margaret T Kasner, Donald E Tsai, et al.
Aquatic Toxicology (Amsterdam, Netherlands)|December 3, 2014
Hypoxia acclimation protects against oxidative damage and changes in prolactin and somatolactin expression in silver catfish (Rhamdia quelen) exposed to manganeseG S Dolci, L T Vey, A J Schuster, et al.
The New England Journal of Medicine|June 24, 2026
Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell LymphomasMarco Ruella, Luca Paruzzo, Emeline R Chong, et al.
International Journal of Radiation Oncology, Biology, Physics|May 25, 2020
Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell LymphomaChristopher M Wright, Michael J LaRiviere, Jonathan A Baron, et al.
Pageof 54